Roles for TGF-β and Programmed Cell Death 1 Ligand 1 in Regulatory T Cell Expansion and Diabetes Suppression by Zymosan in Nonobese Diabetic Mice

被引:25
|
作者
Burton, Oliver T. [1 ]
Zaccone, Paola [1 ]
Phillips, Jenny M. [1 ]
De La Pena, Hugo [1 ,2 ]
Fehervari, Zoltan [1 ]
Azuma, Miyuki [3 ]
Gibbs, Sarah [1 ]
Stockinger, Brigitta [2 ]
Cooke, Anne [1 ]
机构
[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England
[2] Natl Inst Med Res, MRC, Dept Mol Immunol, London NW7 1AA, England
[3] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
来源
JOURNAL OF IMMUNOLOGY | 2010年 / 185卷 / 05期
基金
英国惠康基金; 英国生物技术与生命科学研究理事会;
关键词
PLASMACYTOID DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; NOD MICE; EXTRACELLULAR-MATRIX; RECEPTOR DECTIN-1; CANDIDA-ALBICANS; B-LYMPHOCYTES; IN-VIVO; INDUCTION; PREVENTS;
D O I
10.4049/jimmunol.1001365
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Zymosan is a complex fungal component shown to be capable of both promoting and suppressing the development of autoimmune disorders in mice. In this study, we show that a single injection of zymosan just prior to diabetes onset can significantly delay the progression of disease in NOD mice. Zymosan treatment of NOD mice induced the production of biologically active TGF-beta from cells infiltrating the pancreas and was associated with expansion of programmed cell death 1 ligand 1(+)TGF-beta(+) macrophages and Foxp3(+) regulatory T cells in vivo. Neutralization of either TGF-beta or programmed cell death 1 ligand 1 abrogated the protective effects of zymosan. Zymosan acted through TLR2 as well as ERK and p38 MAPK to induce macrophage secretion of TGF-beta and promotion of Foxp3(+) regulatory T cells in vitro and in vivo. The Journal of Immunology, 2010, 185: 2754-2762.
引用
收藏
页码:2754 / 2762
页数:9
相关论文
共 50 条
  • [31] Identification of programmed cell death 1 and its ligand in the testicular tissue of mice
    Wang, Li-Ling
    Li, Zhi-Hui
    Duan, Yong-Gang
    Yuan, Shui-Qiao
    Mor, Gil
    Liao, Ai-Hua
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2019, 81 (02)
  • [32] Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
    Eissa, Eman
    Kandil, Rania
    El-Ghobashy, Nehal
    Abdelfattah, Walaa
    Hammouda, Zainab
    Gadelsayed, Sara Medhat
    Bayoumi, Faten
    INDIAN JOURNAL OF RHEUMATOLOGY, 2022, 17 (04) : 347 - 352
  • [33] Prognostic implication of programmed cell death 1 protein and programmed cell death 1 ligand 1 expression in endometrial cancer
    Kim, J.
    Choi, J. H.
    Kong, J.
    Yang, W.
    Cho, H.
    Chay, D. B.
    Kim, J. H.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 47 - 47
  • [34] Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
    Lee, Joo Sang
    Ruppin, Eytan
    JAMA ONCOLOGY, 2019, 5 (11) : 1614 - 1618
  • [35] Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
    Pezeshki, Parmida Sadat
    Mahdavi Sharif, Pouya
    Rezaei, Nima
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (12) : 1575 - 1590
  • [36] Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory
    Kazanova, Alexandra
    Rudd, Christopher E.
    PLOS BIOLOGY, 2021, 19 (05)
  • [37] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [38] Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas
    Mikiewicz, Mateusz
    Pazdzior-Czapula, Katarzyna
    Fiedorowicz, Joanna
    Otrocka-Domaga, Iwona
    RESEARCH IN VETERINARY SCIENCE, 2024, 176
  • [39] Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer Reply
    Wang, Zhijie
    Zhao, Zhengyi
    Wang, Jie
    JAMA ONCOLOGY, 2020, 6 (07) : 1116 - +
  • [40] TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice
    Piccirillo, CA
    Chang, YG
    Prud'homme, GJ
    JOURNAL OF IMMUNOLOGY, 1998, 161 (08): : 3950 - 3956